Development of High-Throughput ELISA Based Binding Assays to Detect p53/p63/p73 Family Protein-DNA Interaction in the 96-well Microplate Format for Drug Screening and Other Clinical and Diagnostic Uses

This technology includes ELISA based binding assays of p53, p63 or p73 provide possibilities to validate genome sequencing results, and allow the performance of more in-depth investigation to address scientific mechanisms, as well as to develop applications for high-throughput clinical and diagnosis usages. While quantitative p53 binding assays have been commercially developed, there is a lack of high-throughput method to detect binding activity of all three p53/p63/p73 family members, which are an important step for these transcription factors to perform their function. Targeting these transcription factors is an important strategy for drug development or clinical diagnostics. These binding assays will accelerate such process. Recent technology development of high-throughput sequencing has revealed genome-wide abnormality of p63/p73 binding in cancers. However, there is a lack of a high-throughput technology to validate the results generated from such technology, such as ChIP-seq (Chromatin Immunoprecipitation-parallel sequencing). This technology bridges the gap and provides the necessary validation.